Outlook Therapeutics Sought J-Code for Ophthalmic Drug
The application for a permanent billing code aims to streamline reimbursement for retina practices.
Updated on Oct. 1, 2026 in Healthcare
Live Poll
Should government agencies prioritize faster reimbursement pathways for new, FDA-approved ophthalmic drugs?
Outlook Therapeutics has submitted a request to CMS for a permanent HCPCS Level II J-code for its FDA-approved drug, LYTENAVA. The code is intended to simplify billing and reimbursement for the ophthalmic bevacizumab formulation as the company prepares for a U.S. launch.
Why it matters
Securing a permanent J-code is a critical step for retina practices to ensure clear, consistent reimbursement pathways for physician-administered treatments. This application aims to reduce the administrative burden associated with billing for the therapy ahead of its planned market entry.
The firm reported side effects including conjunctival hemorrhage in 4% of patients and eye pain in 2% of patients, providing safety metrics for a drug launching before the end of 2026. The CMS application process covers all drug and biological code requests on a quarterly basis.
The players
Outlook Therapeutics
A biopharmaceutical company focused on developing and commercializing ophthalmic therapies for retinal diseases.
CMS
The federal agency that administers the Medicare program and maintains the HCPCS Level II code set used for provider reimbursement.
The details
The J-code application allows CMS to evaluate LYTENAVA for a specific billing identifier within the HCPCS Level II code set. By obtaining a permanent product-specific code, Outlook Therapeutics aims to standardize the claim submission process for U.S. retina specialists. While the assignment of a code facilitates administrative efficiency, it does not function as a guarantee of coverage or payment for the product.
Timeline
October 1, 2026: Outlook Therapeutics submitted the J-code application to CMS.
Before the end of 2026: Outlook Therapeutics plans the U.S. commercial launch of LYTENAVA.
Market Landscape
The application process for a permanent J-code is a standard regulatory milestone for pharmaceutical manufacturers navigating the HCPCS Level II code set. This step follows the industry-standard approach for securing reimbursement pathways for physician-administered specialty drugs.
Retina practices should monitor for CMS approval updates, as a permanent J-code will significantly alter the administrative workflow for billing LYTENAVA. Owners should prepare their revenue cycle management systems to integrate new codes once the drug officially enters the market.
The takeaway
Securing a specific J-code is a vital operational milestone for reducing the billing friction common with new ophthalmic biologics. Practice managers should track CMS quarterly decision cycles throughout 2027 to verify if and when the code is officially assigned for clinical use.
Further reading
For more on the regulatory environment for new medical products, see Healthcare.
Live Poll
Should government agencies prioritize faster reimbursement pathways for new, FDA-approved ophthalmic drugs?
